Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment (NCT04143516)
Clinical Trial Optimizing Tumor Ablation for Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures
🩺 Plain-English Summary (8th-Grade Level)
This study will see whether collecting and analyzing needle biopsy samples from cancer liver metastases after a tumor ablation procedure will be able to identify cancer cells that are still alive. The results of these biopsies could help determine the next treatment for your cancer, but the biopsies could cause side effects.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (10 items).
Location: Memorial Sloan Kettering Cancer Center — New York, New York
Age range: 18 Years
🧪 Interventions in This Study
- [18-F]- FDG - PET (DIAGNOSTIC_TEST)
- Tumor ablation (TA) (PROCEDURE)
- PET/CT Scan (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Age \< 18
- Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from ablation injury with technical modifications such as hydro or air dissection
- INR \> 1.5 that cannot be corrected with fresh frozen plasma \*\*
- Platelet count of \<50,000 that cannot be corrected with transfusion
- More than 3 tumors in the liver
- More than 5 tumors of extrahepatic disease (including mediastinal nodes and pulmonary nodules, abdominal or other lymph nodes, and bone metastasis)
- Presence of any peritoneal Carcinomatosis
- For patients on Coumadin, general clinical guidelines for IR ablation will be followed.
- For patients with no FDG-PET avid tumors aim 2 of the protocol will not be assessed
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Memorial Sloan Kettering Cancer Center — New York, New York
📞 Contact the Study Coordinator
Phone: (212) 639-3379
Email: sofoclec@mskcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Liver Metastases
- Proton Therapy in the Treatment of Liver Metastases — Loma Linda, California
- Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases — Montreal, Quebec
- OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases — Madison, Wisconsin
- End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Metastases. — Palo Alto, California
- ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases — Houston, Texas
Explore by condition: All Liver Metastases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.